Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis-Reference-Cited by-同舟云学术

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis

Published:2016-07-11 Issue:10 Volume:36 Page:857-862
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Acanfora Domenico,Acanfora Chiara,Scicchitano Pietro,Longobardi Marialaura,Furgi Giuseppe,Casucci Gerardo,Lanzillo Bernardo,Dentamaro Ilaria,Zito Annapaola,Incalzi Raffaele Antonelli,Ciccone Marco Matteo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-016-0436-5.pdf

Reference23 articles.

1. Connoly SJ, Yusuf S, Eikelboom J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

4. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–3014.

5. Bauersachs R, Berkowitz SD, et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499–510.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Dexmedetomidine on Oxidative Stress, Inflammatory Response, Coagulation Function and Hemodynamics in Patients Undergoing Hysterectomy;International Journal of Anesthesia and Clinical Medicine;2024-04-28

2. Design, synthesis and biological evaluation of Piperazinylanthranilamides as potential factor Xa inhibitors;Journal of Molecular Structure;2022-12

3. Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation;Molecules;2020-01-23

4. FXa Direct Synthetic Inhibitors;Anticoagulant Drugs;2018-08-29

5. Incidence of Visible Hematuria Among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients;Urology;2018-04